Literature DB >> 1384186

The effects of immunosuppressive drugs on the regulation of activation-induced apoptotic cell death in thymocytes.

S A McCarthy1, R N Cacchione, M S Mainwaring, J S Cairns.   

Abstract

This study investigated the effects of immunosuppressive drugs on the regulation of thymocyte sensitivity to clonal deletion via programmed cell death, or apoptosis. We have previously shown that TcR/CD3 cross-linking and intracellular stimuli that mimic TcR/CD3 cross-linking induce apoptosis in many immature thymocytes in the presence, but not in the absence, of cyclosporine (CsA). We have interpreted those results to suggest that TcR/CD3-associated signals induce a CsA-sensitive mechanism that protects the cells from activation-induced apoptosis. In the present study, we compared the effects of CsA, FK506, and rapamycin (RAP) on the regulation of thymocyte apoptosis. Optimal concentrations of CsA and FK506 augmented apoptosis to similar levels. However, FK506 was approximately 100-fold more potent than CsA in thymocytes, which parallels the relative potencies of these drugs in inhibiting mitogen-induced proliferation of mature T cells. In contrast to CsA and FK506, RAP did not exhibit substantial apoptosis-augmenting activity. However, RAP interfered with the activity of FK506. This pattern mirrors that of RAP in TcR/CD3-mediated signaling pathways in mature T cells. Together these results provide evidence (1) that CsA, FK506, and RAP can act on immature thymocytes, (2) that the mechanisms by which the drugs affect mature and immature T cell responses are similar, and (3) that immunosuppressive drug therapy may affect not only mature peripheral T cells but also developing immature thymic T cells.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1384186     DOI: 10.1097/00007890-199209000-00029

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  8 in total

1.  Apoptosis of graft-infiltrating cytotoxic T cells: a mechanism underlying "split tolerance" in mouse liver transplantation.

Authors:  S Qian; L Lu; Y Li; F Fu; W Li; T E Starzl; A W Thomson; J J Fung
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

2.  Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction.

Authors:  S Qian; L Lu; F Fu; Y Li; W Li; T E Starzl; J J Fung; A W Thomson
Journal:  J Immunol       Date:  1997-05-15       Impact factor: 5.422

3.  Blocking of the B7-CD28 pathway increases apoptosis induced in activated T cells by in vitro-generated CD95L (FasL) positive dendritic cells.

Authors:  L Lu; S Qian; P Hershberger; W A Rudert; Y Li; F G Chambers; T E Starzl; D H Lynch; A W Thomson
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

4.  Regulation of apoptosis in transgenic mice by simian virus 40 T antigen-mediated inactivation of p53.

Authors:  S A McCarthy; H S Symonds; T Van Dyke
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-26       Impact factor: 11.205

5.  Inhibitory effect of the immunosuppressant FK506 on apoptotic cell death induced by HIV-1 gp120.

Authors:  I Sekigawa; K Koshino; T Hishikawa; H Kaneko; Y Takasaki; H Hashimoto; S Hirose; Y Inagaki; N Yamamoto
Journal:  J Clin Immunol       Date:  1995-11       Impact factor: 8.317

6.  Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity.

Authors:  C P Delaney; N Murase; M Chen-Woan; J J Fung; T E Starzl; A J Demetris
Journal:  J Clin Invest       Date:  1996-01-01       Impact factor: 14.808

7.  Identification of immunosuppressant-induced apoptosis in a murine B-cell line and its prevention by bcl-x but not bcl-2.

Authors:  A R Gottschalk; L H Boise; C B Thompson; J Quintáns
Journal:  Proc Natl Acad Sci U S A       Date:  1994-07-19       Impact factor: 11.205

8.  The effects of in vivo cyclosporin A administration on rat thymic dendritic cells.

Authors:  J G Damoiseaux; L J Beijleveld; P J van Breda Vriesman
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.